Press Release – February 20, 2013

San Diego, February 20, 2013 – Ventrix, Inc. announced today that its VentriGelâ„¢ cardiac repair scaffold safely and effectively mitigated left ventricular remodeling and improved cardiac function in pigs after myocardial infarction, or heart attack. The findings, made during pre-clinical studies, were published today in the journal Science Translational Medicine. Based on these and other results, Ventrix has begun taking steps to initiate a first-in-man clinical trial for VentriGel.

Download the full February 20th Press Release, click here.